Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ATTR therapy.
from mint - science https://ift.tt/3SRmnx4
Monday, 27 October 2025
Intellia pauses Phase 3 CRISPR trial as patient develops serious liver reaction to therapy called nex-z
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment